Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,654
archived clinical trials in
Cardiology

The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  3/15/2017
Clinical Research Facility
mi
from
Portland, OR
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 3/15/2017
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  3/15/2017
Clinical Research Facility
mi
from
Florence, SC
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 3/15/2017
Clinical Research Facility
mi
from
Florence, SC
Click here to add this to my saved trials
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  3/15/2017
Clinical Research Facility
mi
from
Rapid City, SD
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 3/15/2017
Clinical Research Facility
mi
from
Rapid City, SD
Click here to add this to my saved trials
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  3/15/2017
Clinical Research Facility
mi
from
Nashville, TN
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 3/15/2017
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  3/15/2017
Clinical Research Facility
mi
from
Abilene, TX
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 3/15/2017
Clinical Research Facility
mi
from
Abilene, TX
Click here to add this to my saved trials
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  3/15/2017
Clinical Research Facility
mi
from
Austin, TX
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 3/15/2017
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  3/15/2017
Clinical Research Facility
mi
from
Fort Worth, TX
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 3/15/2017
Clinical Research Facility
mi
from
Fort Worth, TX
Click here to add this to my saved trials
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  3/15/2017
Clinical Research Facility
mi
from
Houston, TX
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 3/15/2017
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  3/15/2017
Clinical Research Facility
mi
from
McAllen, TX
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 3/15/2017
Clinical Research Facility
mi
from
McAllen, TX
Click here to add this to my saved trials
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  3/15/2017
Clinical Research Facility
mi
from
San Antonio, TX
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 3/15/2017
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  3/15/2017
Clinical Research Facility
mi
from
Salt Lake City, UT
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 3/15/2017
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  3/15/2017
Clinical Research Facility
mi
from
Warrenton, VA
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 3/15/2017
Clinical Research Facility
mi
from
Warrenton, VA
Click here to add this to my saved trials
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  3/15/2017
Clinical Research Facility
mi
from
Pheonix, AZ
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 3/15/2017
Clinical Research Facility
mi
from
Pheonix, AZ
Click here to add this to my saved trials
Aortic Dissection Detection Risk Score Plus D-dimer in Suspected Acute Aortic Dissection
Aortic Dissection Detection Risk Score Plus D-dimer in the Diagnostic Workup of Suspected Acute Aortic Dissection: a Prospective Multicenter Study
Status: Enrolling
Updated:  3/15/2017
Emergency Department. Massachusetts General Hospital
mi
from
Boston, MA
Aortic Dissection Detection Risk Score Plus D-dimer in Suspected Acute Aortic Dissection
Aortic Dissection Detection Risk Score Plus D-dimer in the Diagnostic Workup of Suspected Acute Aortic Dissection: a Prospective Multicenter Study
Status: Enrolling
Updated: 3/15/2017
Emergency Department. Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Aortic Dissection Detection Risk Score Plus D-dimer in Suspected Acute Aortic Dissection
Aortic Dissection Detection Risk Score Plus D-dimer in the Diagnostic Workup of Suspected Acute Aortic Dissection: a Prospective Multicenter Study
Status: Enrolling
Updated:  3/15/2017
Heart Institute, University of Sao Paolo
mi
from
Sao Paolo,
Aortic Dissection Detection Risk Score Plus D-dimer in Suspected Acute Aortic Dissection
Aortic Dissection Detection Risk Score Plus D-dimer in the Diagnostic Workup of Suspected Acute Aortic Dissection: a Prospective Multicenter Study
Status: Enrolling
Updated: 3/15/2017
Heart Institute, University of Sao Paolo
mi
from
Sao Paolo,
Click here to add this to my saved trials
Swept-Source Optical Coherence Tomography for Noninvasive Retinal Vascular Imaging
Swept-Source Optical Coherence Tomography for Noninvasive Retinal Vascular Imaging
Status: Enrolling
Updated:  3/20/2017
Duke Eye Center
mi
from
Durham, NC
Swept-Source Optical Coherence Tomography for Noninvasive Retinal Vascular Imaging
Swept-Source Optical Coherence Tomography for Noninvasive Retinal Vascular Imaging
Status: Enrolling
Updated: 3/20/2017
Duke Eye Center
mi
from
Durham, NC
Click here to add this to my saved trials
Study to Assess the Safety and Cardiovascular Effects of Autologous Adipose-Derived Stromal Cells Implantation In Patients During the Acute Recovery Phase of ST-Elevation Myocardial Infarction
An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Cardiovascular Effects of Autologous Adipose-Derived Stromal Cells Implantation by a Catheter Delivery System and/or Intravenously In Patients During the Acute Recovery Phase of ST-Elevation Myocardial Infarction
Status: Enrolling
Updated:  3/20/2017
Ageless Institute
mi
from
Miami, FL
Study to Assess the Safety and Cardiovascular Effects of Autologous Adipose-Derived Stromal Cells Implantation In Patients During the Acute Recovery Phase of ST-Elevation Myocardial Infarction
An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Cardiovascular Effects of Autologous Adipose-Derived Stromal Cells Implantation by a Catheter Delivery System and/or Intravenously In Patients During the Acute Recovery Phase of ST-Elevation Myocardial Infarction
Status: Enrolling
Updated: 3/20/2017
Ageless Institute
mi
from
Miami, FL
Click here to add this to my saved trials
Doppler Ultrasound Following Unicondylar Knee Replacement to Determine the Incidence of Postoperative DVT
Doppler Ultrasound Following Unicondylar Knee Replacement to Determine the Incidence of Postoperative DVT
Status: Enrolling
Updated:  3/20/2017
Hospital for Special Surgery
mi
from
New York, NY
Doppler Ultrasound Following Unicondylar Knee Replacement to Determine the Incidence of Postoperative DVT
Doppler Ultrasound Following Unicondylar Knee Replacement to Determine the Incidence of Postoperative DVT
Status: Enrolling
Updated: 3/20/2017
Hospital for Special Surgery
mi
from
New York, NY
Click here to add this to my saved trials
Coronary Computed Tomographic Angiography for Selective Cardiac Catheterization
Coronary Computed Tomographic Angiography for Selective Cardiac Catheterization: Relation to CardioVascular Outcomes, Cost Effectiveness and Quality of Life
Status: Enrolling
Updated:  3/21/2017
Walter Reed Medical Center
mi
from
Bethesda, MD
Coronary Computed Tomographic Angiography for Selective Cardiac Catheterization
Coronary Computed Tomographic Angiography for Selective Cardiac Catheterization: Relation to CardioVascular Outcomes, Cost Effectiveness and Quality of Life
Status: Enrolling
Updated: 3/21/2017
Walter Reed Medical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Coronary Computed Tomographic Angiography for Selective Cardiac Catheterization
Coronary Computed Tomographic Angiography for Selective Cardiac Catheterization: Relation to CardioVascular Outcomes, Cost Effectiveness and Quality of Life
Status: Enrolling
Updated:  3/21/2017
Quanta Diagnostico Nuclear, Curitiba-PR
mi
from
Curitiba,
Coronary Computed Tomographic Angiography for Selective Cardiac Catheterization
Coronary Computed Tomographic Angiography for Selective Cardiac Catheterization: Relation to CardioVascular Outcomes, Cost Effectiveness and Quality of Life
Status: Enrolling
Updated: 3/21/2017
Quanta Diagnostico Nuclear, Curitiba-PR
mi
from
Curitiba,
Click here to add this to my saved trials
Renal Denervation in Patients With Uncontrolled Hypertension - SYMPLICITY HTN-4
Renal Denervation Using the SYMPLICITY Renal Denervation System in Patients With Uncontrolled Hypertension - SYMPLICITY HTN-4
Status: Enrolling
Updated:  3/21/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Renal Denervation in Patients With Uncontrolled Hypertension - SYMPLICITY HTN-4
Renal Denervation Using the SYMPLICITY Renal Denervation System in Patients With Uncontrolled Hypertension - SYMPLICITY HTN-4
Status: Enrolling
Updated: 3/21/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Renal Denervation in Patients With Uncontrolled Hypertension - SYMPLICITY HTN-4
Renal Denervation Using the SYMPLICITY Renal Denervation System in Patients With Uncontrolled Hypertension - SYMPLICITY HTN-4
Status: Enrolling
Updated:  3/21/2017
Piedmont Hospital
mi
from
Atlanta, GA
Renal Denervation in Patients With Uncontrolled Hypertension - SYMPLICITY HTN-4
Renal Denervation Using the SYMPLICITY Renal Denervation System in Patients With Uncontrolled Hypertension - SYMPLICITY HTN-4
Status: Enrolling
Updated: 3/21/2017
Piedmont Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Renal Denervation in Patients With Uncontrolled Hypertension - SYMPLICITY HTN-4
Renal Denervation Using the SYMPLICITY Renal Denervation System in Patients With Uncontrolled Hypertension - SYMPLICITY HTN-4
Status: Enrolling
Updated:  3/21/2017
Medical University of South Carolina
mi
from
Charleston, SC
Renal Denervation in Patients With Uncontrolled Hypertension - SYMPLICITY HTN-4
Renal Denervation Using the SYMPLICITY Renal Denervation System in Patients With Uncontrolled Hypertension - SYMPLICITY HTN-4
Status: Enrolling
Updated: 3/21/2017
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Physicians International CT Utilization Registry 2
Big PICTURE 2: Physicians International CT Utilization Registry 2
Status: Enrolling
Updated:  3/21/2017
MDDX
mi
from
San Francisco, CA
Physicians International CT Utilization Registry 2
Big PICTURE 2: Physicians International CT Utilization Registry 2
Status: Enrolling
Updated: 3/21/2017
MDDX
mi
from
San Francisco, CA
Click here to add this to my saved trials
Physicians International CT Utilization Registry 2
Big PICTURE 2: Physicians International CT Utilization Registry 2
Status: Enrolling
Updated:  3/21/2017
FACTS
mi
from
Hyderabad,
Physicians International CT Utilization Registry 2
Big PICTURE 2: Physicians International CT Utilization Registry 2
Status: Enrolling
Updated: 3/21/2017
FACTS
mi
from
Hyderabad,
Click here to add this to my saved trials
A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure
A Phase IIa Study of the Safety, Tolerability and Hemodynamic Effects of a Continuous 6 Hour Intravenous Infusion of CXL-1427 in Hospitalized Patients With Systolic Heart Failure
Status: Enrolling
Updated:  3/22/2017
Cardioxyl Study Site
mi
from
Gainesville, FL
A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure
A Phase IIa Study of the Safety, Tolerability and Hemodynamic Effects of a Continuous 6 Hour Intravenous Infusion of CXL-1427 in Hospitalized Patients With Systolic Heart Failure
Status: Enrolling
Updated: 3/22/2017
Cardioxyl Study Site
mi
from
Gainesville, FL
Click here to add this to my saved trials
A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure
A Phase IIa Study of the Safety, Tolerability and Hemodynamic Effects of a Continuous 6 Hour Intravenous Infusion of CXL-1427 in Hospitalized Patients With Systolic Heart Failure
Status: Enrolling
Updated:  3/22/2017
Cardioxyl Study Site
mi
from
Jacksonville, FL
A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure
A Phase IIa Study of the Safety, Tolerability and Hemodynamic Effects of a Continuous 6 Hour Intravenous Infusion of CXL-1427 in Hospitalized Patients With Systolic Heart Failure
Status: Enrolling
Updated: 3/22/2017
Cardioxyl Study Site
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure
A Phase IIa Study of the Safety, Tolerability and Hemodynamic Effects of a Continuous 6 Hour Intravenous Infusion of CXL-1427 in Hospitalized Patients With Systolic Heart Failure
Status: Enrolling
Updated:  3/22/2017
Cardioxyl Study Site
mi
from
Jacksonville, FL
A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure
A Phase IIa Study of the Safety, Tolerability and Hemodynamic Effects of a Continuous 6 Hour Intravenous Infusion of CXL-1427 in Hospitalized Patients With Systolic Heart Failure
Status: Enrolling
Updated: 3/22/2017
Cardioxyl Study Site
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure
A Phase IIa Study of the Safety, Tolerability and Hemodynamic Effects of a Continuous 6 Hour Intravenous Infusion of CXL-1427 in Hospitalized Patients With Systolic Heart Failure
Status: Enrolling
Updated:  3/22/2017
Cardioxyl Study Site
mi
from
Macon, GA
A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure
A Phase IIa Study of the Safety, Tolerability and Hemodynamic Effects of a Continuous 6 Hour Intravenous Infusion of CXL-1427 in Hospitalized Patients With Systolic Heart Failure
Status: Enrolling
Updated: 3/22/2017
Cardioxyl Study Site
mi
from
Macon, GA
Click here to add this to my saved trials
A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure
A Phase IIa Study of the Safety, Tolerability and Hemodynamic Effects of a Continuous 6 Hour Intravenous Infusion of CXL-1427 in Hospitalized Patients With Systolic Heart Failure
Status: Enrolling
Updated:  3/22/2017
Cardioxyl Study Site
mi
from
Baltimore, MD
A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure
A Phase IIa Study of the Safety, Tolerability and Hemodynamic Effects of a Continuous 6 Hour Intravenous Infusion of CXL-1427 in Hospitalized Patients With Systolic Heart Failure
Status: Enrolling
Updated: 3/22/2017
Cardioxyl Study Site
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure
A Phase IIa Study of the Safety, Tolerability and Hemodynamic Effects of a Continuous 6 Hour Intravenous Infusion of CXL-1427 in Hospitalized Patients With Systolic Heart Failure
Status: Enrolling
Updated:  3/22/2017
Cardioxyl Study Site
mi
from
Detroit, MI
A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure
A Phase IIa Study of the Safety, Tolerability and Hemodynamic Effects of a Continuous 6 Hour Intravenous Infusion of CXL-1427 in Hospitalized Patients With Systolic Heart Failure
Status: Enrolling
Updated: 3/22/2017
Cardioxyl Study Site
mi
from
Detroit, MI
Click here to add this to my saved trials
A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure
A Phase IIa Study of the Safety, Tolerability and Hemodynamic Effects of a Continuous 6 Hour Intravenous Infusion of CXL-1427 in Hospitalized Patients With Systolic Heart Failure
Status: Enrolling
Updated:  3/22/2017
Cardioxyl Study Site
mi
from
Newark, NJ
A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure
A Phase IIa Study of the Safety, Tolerability and Hemodynamic Effects of a Continuous 6 Hour Intravenous Infusion of CXL-1427 in Hospitalized Patients With Systolic Heart Failure
Status: Enrolling
Updated: 3/22/2017
Cardioxyl Study Site
mi
from
Newark, NJ
Click here to add this to my saved trials
A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure
A Phase IIa Study of the Safety, Tolerability and Hemodynamic Effects of a Continuous 6 Hour Intravenous Infusion of CXL-1427 in Hospitalized Patients With Systolic Heart Failure
Status: Enrolling
Updated:  3/22/2017
Cardioxyl Study Site
mi
from
Chapel Hill, NC
A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure
A Phase IIa Study of the Safety, Tolerability and Hemodynamic Effects of a Continuous 6 Hour Intravenous Infusion of CXL-1427 in Hospitalized Patients With Systolic Heart Failure
Status: Enrolling
Updated: 3/22/2017
Cardioxyl Study Site
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure
A Phase IIa Study of the Safety, Tolerability and Hemodynamic Effects of a Continuous 6 Hour Intravenous Infusion of CXL-1427 in Hospitalized Patients With Systolic Heart Failure
Status: Enrolling
Updated:  3/22/2017
Cardioxyl Study Site
mi
from
Cincinnati, OH
A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure
A Phase IIa Study of the Safety, Tolerability and Hemodynamic Effects of a Continuous 6 Hour Intravenous Infusion of CXL-1427 in Hospitalized Patients With Systolic Heart Failure
Status: Enrolling
Updated: 3/22/2017
Cardioxyl Study Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure
A Phase IIa Study of the Safety, Tolerability and Hemodynamic Effects of a Continuous 6 Hour Intravenous Infusion of CXL-1427 in Hospitalized Patients With Systolic Heart Failure
Status: Enrolling
Updated:  3/22/2017
Cardioxyl Study Site
mi
from
Columbus, OH
A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure
A Phase IIa Study of the Safety, Tolerability and Hemodynamic Effects of a Continuous 6 Hour Intravenous Infusion of CXL-1427 in Hospitalized Patients With Systolic Heart Failure
Status: Enrolling
Updated: 3/22/2017
Cardioxyl Study Site
mi
from
Columbus, OH
Click here to add this to my saved trials
A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure
A Phase IIa Study of the Safety, Tolerability and Hemodynamic Effects of a Continuous 6 Hour Intravenous Infusion of CXL-1427 in Hospitalized Patients With Systolic Heart Failure
Status: Enrolling
Updated:  3/22/2017
Cardioxyl Study Site
mi
from
Charleston, SC
A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure
A Phase IIa Study of the Safety, Tolerability and Hemodynamic Effects of a Continuous 6 Hour Intravenous Infusion of CXL-1427 in Hospitalized Patients With Systolic Heart Failure
Status: Enrolling
Updated: 3/22/2017
Cardioxyl Study Site
mi
from
Charleston, SC
Click here to add this to my saved trials
A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure
A Phase IIa Study of the Safety, Tolerability and Hemodynamic Effects of a Continuous 6 Hour Intravenous Infusion of CXL-1427 in Hospitalized Patients With Systolic Heart Failure
Status: Enrolling
Updated:  3/22/2017
Cardioxyl Study Site
mi
from
Nashville, TN
A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure
A Phase IIa Study of the Safety, Tolerability and Hemodynamic Effects of a Continuous 6 Hour Intravenous Infusion of CXL-1427 in Hospitalized Patients With Systolic Heart Failure
Status: Enrolling
Updated: 3/22/2017
Cardioxyl Study Site
mi
from
Nashville, TN
Click here to add this to my saved trials
A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure
A Phase IIa Study of the Safety, Tolerability and Hemodynamic Effects of a Continuous 6 Hour Intravenous Infusion of CXL-1427 in Hospitalized Patients With Systolic Heart Failure
Status: Enrolling
Updated:  3/22/2017
Cardioxyl Study Site
mi
from
Salt lake City, UT
A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure
A Phase IIa Study of the Safety, Tolerability and Hemodynamic Effects of a Continuous 6 Hour Intravenous Infusion of CXL-1427 in Hospitalized Patients With Systolic Heart Failure
Status: Enrolling
Updated: 3/22/2017
Cardioxyl Study Site
mi
from
Salt lake City, UT
Click here to add this to my saved trials
A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure
A Phase IIa Study of the Safety, Tolerability and Hemodynamic Effects of a Continuous 6 Hour Intravenous Infusion of CXL-1427 in Hospitalized Patients With Systolic Heart Failure
Status: Enrolling
Updated:  3/22/2017
Cardioxyl Study Site
mi
from
Richmond, VA
A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure
A Phase IIa Study of the Safety, Tolerability and Hemodynamic Effects of a Continuous 6 Hour Intravenous Infusion of CXL-1427 in Hospitalized Patients With Systolic Heart Failure
Status: Enrolling
Updated: 3/22/2017
Cardioxyl Study Site
mi
from
Richmond, VA
Click here to add this to my saved trials
A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure
A Phase IIa Study of the Safety, Tolerability and Hemodynamic Effects of a Continuous 6 Hour Intravenous Infusion of CXL-1427 in Hospitalized Patients With Systolic Heart Failure
Status: Enrolling
Updated:  3/22/2017
Cardioxyl Study Site
mi
from
Bad Neuheim,
A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure
A Phase IIa Study of the Safety, Tolerability and Hemodynamic Effects of a Continuous 6 Hour Intravenous Infusion of CXL-1427 in Hospitalized Patients With Systolic Heart Failure
Status: Enrolling
Updated: 3/22/2017
Cardioxyl Study Site
mi
from
Bad Neuheim,
Click here to add this to my saved trials
Prospective Randomized Evaluation of an Ultra Conservative Approach to Implantable Defibrillator (ICD) Programming in Patients With a Left Ventricular Assist Device (LVAD).
Prospective Randomized Evaluation of an Ultra Conservative Approach to Implantable Defibrillator (ICD) Programming in Patients With a Left Ventricular Assist Device (LVAD).
Status: Enrolling
Updated:  3/23/2017
Vanderbilt University
mi
from
Nashville, TN
Prospective Randomized Evaluation of an Ultra Conservative Approach to Implantable Defibrillator (ICD) Programming in Patients With a Left Ventricular Assist Device (LVAD).
Prospective Randomized Evaluation of an Ultra Conservative Approach to Implantable Defibrillator (ICD) Programming in Patients With a Left Ventricular Assist Device (LVAD).
Status: Enrolling
Updated: 3/23/2017
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
Feasibility Study of Exercise in Patients With Leg Blood Clots
EXPERT Trial: Exercise to Prevent Post-thrombotic Syndrome Elicited by Recent Thrombosis
Status: Enrolling
Updated:  3/27/2017
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Feasibility Study of Exercise in Patients With Leg Blood Clots
EXPERT Trial: Exercise to Prevent Post-thrombotic Syndrome Elicited by Recent Thrombosis
Status: Enrolling
Updated: 3/27/2017
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
VTE Prophylaxis Guidelines in Hospitalized Elders
Adherence to Venous Thromboembolism Prophylaxis Guidelines in Hospitalized Elders
Status: Enrolling
Updated:  3/30/2017
Duke Univ Med Ctr
mi
from
Durham, NC
VTE Prophylaxis Guidelines in Hospitalized Elders
Adherence to Venous Thromboembolism Prophylaxis Guidelines in Hospitalized Elders
Status: Enrolling
Updated: 3/30/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Association Between a Mother's Exposure to "Strep Throat" and Her Baby's Developing Heart Disease
Evaluation of Maternal B-hemolytic Streptococcal Pharyngeal Exposure in Pregnancies Affected by Congenital Heart Disease(CHD)
Status: Enrolling
Updated:  4/3/2017
St Louis Children's Hospital
mi
from
St Louis, MO
Association Between a Mother's Exposure to "Strep Throat" and Her Baby's Developing Heart Disease
Evaluation of Maternal B-hemolytic Streptococcal Pharyngeal Exposure in Pregnancies Affected by Congenital Heart Disease(CHD)
Status: Enrolling
Updated: 4/3/2017
St Louis Children's Hospital
mi
from
St Louis, MO
Click here to add this to my saved trials
Association Between a Mother's Exposure to "Strep Throat" and Her Baby's Developing Heart Disease
Evaluation of Maternal B-hemolytic Streptococcal Pharyngeal Exposure in Pregnancies Affected by Congenital Heart Disease(CHD)
Status: Enrolling
Updated:  4/3/2017
Cincinatti Children's Hospital Medical Center
mi
from
Cincinatti, OH
Association Between a Mother's Exposure to "Strep Throat" and Her Baby's Developing Heart Disease
Evaluation of Maternal B-hemolytic Streptococcal Pharyngeal Exposure in Pregnancies Affected by Congenital Heart Disease(CHD)
Status: Enrolling
Updated: 4/3/2017
Cincinatti Children's Hospital Medical Center
mi
from
Cincinatti, OH
Click here to add this to my saved trials
Exparel as a Nerve Block for Severe Hand Pain
Chemical Sympathectomy Following Peripheral Nerve Block With Liposomal Bupivacaine
Status: Enrolling
Updated:  4/3/2017
Ochsner Clinic Foundation
mi
from
New Orleans, LA
Exparel as a Nerve Block for Severe Hand Pain
Chemical Sympathectomy Following Peripheral Nerve Block With Liposomal Bupivacaine
Status: Enrolling
Updated: 4/3/2017
Ochsner Clinic Foundation
mi
from
New Orleans, LA
Click here to add this to my saved trials
VIDA Mobile Health Cardiovascular Prevention Program
A Lifestyle-Based Mobile Health Strategy for Cardiovascular Disease Prevention in Graduates From Cardiac Rehabilitation: VIDA Pilot Study
Status: Enrolling
Updated:  4/3/2017
Duke Medicine - Duke Molecular Physiology Institute
mi
from
Durham, NC
VIDA Mobile Health Cardiovascular Prevention Program
A Lifestyle-Based Mobile Health Strategy for Cardiovascular Disease Prevention in Graduates From Cardiac Rehabilitation: VIDA Pilot Study
Status: Enrolling
Updated: 4/3/2017
Duke Medicine - Duke Molecular Physiology Institute
mi
from
Durham, NC
Click here to add this to my saved trials
Combined Illness Management and Psychotherapy in Treating Depressed Elders
Combined Illness Management and Psychotherapy in Treating Depressed Elders
Status: Enrolling
Updated:  4/4/2017
Iowa City VA Health Care System
mi
from
Iowa City, IA
Combined Illness Management and Psychotherapy in Treating Depressed Elders
Combined Illness Management and Psychotherapy in Treating Depressed Elders
Status: Enrolling
Updated: 4/4/2017
Iowa City VA Health Care System
mi
from
Iowa City, IA
Click here to add this to my saved trials
Combined Illness Management and Psychotherapy in Treating Depressed Elders
Combined Illness Management and Psychotherapy in Treating Depressed Elders
Status: Enrolling
Updated:  4/4/2017
University of Iowa
mi
from
Iowa City, IA
Combined Illness Management and Psychotherapy in Treating Depressed Elders
Combined Illness Management and Psychotherapy in Treating Depressed Elders
Status: Enrolling
Updated: 4/4/2017
University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
Weight Based Enoxaparin in Trauma Patients
Weight Based Enoxaparin for Venous Thromboembolism Prophylaxis in Trauma Patients
Status: Enrolling
Updated:  4/4/2017
Intermountain Medical Center
mi
from
Murray, UT
Weight Based Enoxaparin in Trauma Patients
Weight Based Enoxaparin for Venous Thromboembolism Prophylaxis in Trauma Patients
Status: Enrolling
Updated: 4/4/2017
Intermountain Medical Center
mi
from
Murray, UT
Click here to add this to my saved trials